COMP <GO>
RIGL vs MRK // EV/EBITDA & P/E VALUATION
Rigel Pharmaceuticals Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: RIGL 8
— MRK 3
▲ EV/EBITDA & P/E VALUATION LEADER: RIGL
LAST: $51.31 (-0.27%) • MKT CAP: $961.1M
valuation
7.3x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RIGL VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RIGL | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.30% | 74.80% | +18.50 | RIGL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 28.20% | 20.70% | +7.50 | RIGL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.3x | 15.3x | -8.00 | RIGL | /valuation <GO> |
| Free Cash Flow Yield | 7.87% | 3.42% | +4.45 | RIGL | /fcf-yield <GO> |
| Operating Margin | 42.60% | 34.30% | +8.30 | RIGL | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | RIGL | /net-margins <GO> |
| Revenue Growth (YoY) | 64.10% | 1.30% | +62.80 | RIGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.64 | 5.19 | -1.55 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.9 | 51.7 | +13.20 | RIGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $961.1M | $361.02B | -$360.06B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RIGL REV | MRK REV | RIGL GROSS % | MRK GROSS % | RIGL FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $294.3M | $65.01B | 93.3% | 74.8% | $75.7M | $12.36B |
| FY 2024 | $179.3M | $64.17B | 89.6% | 76.3% | $31.5M | $18.10B |
| FY 2023 | $116.9M | $60.12B | — | — | -$5.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RIGL // BETA —
MRK // BETA 0.92